Rapid imaging of human melanoma xenografts using an scFv fragment of the human monoclonal antibody H11 labelled with 111In

H11 is a human IgM monoclonal antibody which recognizes a novel tumour-associated antigen expressed on melanoma, glioma, breast cancer, colon cancer, prostate cancer, lung cancer and B-cell lymphoma. In this study, a recombinant single-chain Fv (scFv) fragment of H11 labelled with 111In was investigated for tumour imaging in athymic mice implanted subcutaneously with A-375 human melanoma xenografts. H11 scFv was derivatized with diethylenetriaminepentaacetic acid (DTPA) for labelling with 111In. The immunoreactivity of DTPA-H11 scFv against A-375 cells in vitro ranged from 23% to 36%. 111In-DTPA-H11 scFv was rapidly eliminated from the blood and most normal tissues (except the kidneys) reaching maximum tumour/blood ratios of 12:1 at 48 h post-injection. Tumours were imaged as early as 40 min after injection. The kidneys accumulated the highest concentration of radioactivity (up to 185% injected dose/g). Tumour uptake was 1-3% injected dose/g. The whole-body radiation absorbed dose predicted for administration of 185 MBq of 111In-DTPA-H11 scFv to humans was 37 mSv. The radiation absorbed dose estimates for the kidneys, spleen and intestines were 405 mSv, 698 mSv and 412 mSv, respectively. The results of this preclinical study and a concurrent phase I trial suggest a promising role for H11 scFv for tumour imaging.

[1]  P. Weiden,et al.  Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy. , 1997, Clinical nuclear medicine.

[2]  David M. Goldenberg,et al.  Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations , 1998, European Journal of Nuclear Medicine.

[3]  R. Hawkins,et al.  Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial library , 1996, Nature Medicine.

[4]  Abdel-Nabi Hh,et al.  Multicenter clinical trials of monoclonal antibody B72.3-GYK-DTPA 111In (111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma. , 1992 .

[5]  S. Gallinger,et al.  Problems of Delivery of Monoclonal Antibodies , 1995, Clinical pharmacokinetics.

[6]  C. MacKenzie,et al.  Production, crystallization and diffraction to atomic resolution of an antibody Fv specific for the blood-group A oligosaccharide antigen. , 1998, Acta crystallographica. Section D, Biological crystallography.

[7]  S. Houle,et al.  In vitro stability of EDTA and DTPA immunoconjugates of monoclonal antibody 2G3 labeled with indium-111. , 1992, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[8]  R. Reba,et al.  Factors influencing DTPA conjugation with antibodies by cyclic DTPA anhydride. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  H. Mantsch,et al.  Noninvasive localization of tumors by immunofluorescence imaging using a single chain Fv fragment of a human monoclonal antibody with broad cancer specificity , 2000, Cancer.

[10]  K A Chester,et al.  Preclinical characterization and in vivo imaging studies of an engineered recombinant technetium-99m-labeled metallothionein-containing anti-carcinoembryonic antigen single-chain antibody. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  Y. Katakura,et al.  Cell hybridization, hybridomas, and human hybridomas. , 1998, Methods in cell biology.

[12]  S. Batra,et al.  Pharmacokinetics and biodistribution of genetically engineered antibodies. , 2002, Current opinion in biotechnology.

[13]  G. Adams,et al.  Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. , 1998, Cancer research.

[14]  T. Yokota,et al.  Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. , 1991, Cancer research.

[15]  T. Yokota,et al.  Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules. , 1992, Cancer research.

[16]  S. Gallinger,et al.  Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. , 1993, Cancer research.

[17]  J Gariépy,et al.  Factors influencing the sensitivity of tumor imaging with a receptor-binding radiopharmaceutical. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  L E Williams,et al.  Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. , 1996, Cancer research.

[19]  S. Batra,et al.  Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  I. Pastan,et al.  L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. , 1996, Cancer research.

[21]  R. Begent,et al.  A single chain Fv derived from a filamentous phage library has distinct tumour targeting advantages over one derived from a hybridoma , 1995, International journal of cancer.

[22]  I. Pastan,et al.  Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors. , 1995, Cancer research.

[23]  D. Goldenberg,et al.  Breast cancer imaging with radiolabeled antibodies. , 1999, Seminars in nuclear medicine.